OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), an international medical gadget business concentrating on interventional gadgets for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) treatments, today revealed its interim outcomes for the 6 months ended June 30, 2025 (the “Period”), reporting development in both profits and net revenue in spite of an unpredictable macroeconomic landscape.
The Group tape-recorded profits of US$ 83.6 million, up 5.9% over the previous year, driven by strong year-on-year development in the United States market, in addition to continued contributions from emerging markets in APAC and EMEA. Core operating earnings, being revenue attributable to the owners of the Company omitting share-based settlement, net tax credit from delayed tax property in relation to tax losses, and financing income/costs, totaled up to US$ 15.1 million, up by 11.4% year-on-year. Earnings attributable to the owners of the Company increased by 5.1% year-on-year to US$ 19.8 million. Standard revenues per share was US2.40 cents (very first half of 2024: US2.28 cents).
Since June 30, 2025, the Group kept a strong monetary position with money and bank balances totaling up to US$ 237.1 million. Due to the Group’s strong monetary position and in event of the its 25th anniversary, the Board has actually fixed to state an unique dividend of HK15 cents per regular share, showing the Group’s dedication to developing worth for its Shareholders. Together with the last dividend of HK10 cents per share for the year ended December 31, 2024 paid on June 16, 2025, Shareholders will get an overall dividend of HK25 cents in 2025.
Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeichstated, “Over the previous 25 years, we have actually constantly purchased development and international industrial abilities, developing OrbusNeich’s track record and allowing us to browse various financial cycles. Regardless of macroeconomic and geopolitical obstacles in the very first half of 2025, our worldwide implementation showed resistant. Development in the United States market showed strong need for our premium items, while our comprehensive sales network effectively recorded development chances in the APAC and EMEA areas. We will continue to hone our one-upmanship by boosting brand name worth through our direct sales market existence, exceptional sales assistance, dedication to development, and extensive PCI and PTA item portfolio, while advancing more secure, more efficient services for doctors and clients and providing long-lasting go back to investors.”
International Sales Network and Partnerships Boost Revenue Growth
OrbusNeich has actually developed a sales network covering over 70 nations and areas, consisting of direct groups in 13 areas and an international supplier network, which showed important to recording regional chances and need worldwide. APAC income increased by 14.0% year-on-year to US$ 27.3 million throughout the Period, sustained by development in Indonesia and increasing adoption of Scoreflex TRIO in Singapore and Malaysia. EMEA income grew 17.0% to US$ 22.4 million, driven by strong exclusive balloon item sales in crucial direct markets (Germany, France, Spain) and supplier markets (the UK, Slovakia, Czech Republic). Regardless of tariff interruptions, United States income increased by 20.0% to US$ 8.0 million, increased by a noteworthy rise in sales volume of basic and scoring coronary balloons and peripheral balloons, consisting of the pricey Scoreflex NC balloon. Profits from the Japan and PRC markets was US$ 16.1 million and US$ 9.7 million, respectively.
Leveraging its widely-recognized worldwide commercialization know-how, the Group partnered with peers pursuing worldwide growth to enhance its item portfolio and drive extra income streams. Structure on the effective cooperation with SonoScape Medical Corp. including the circulation of intravascular ultrasound (“IVUS”) items in Hong Kong and Macau in 2015, the Group has actually participated in a sole and special circulation arrangement with this partner to disperse its IVUS items in Singapore and Malaysia. The partnership now covers 4 extra direct European markets (France, Germany, Spain, Switzerland) and 6 other supplier markets throughout Europe.
Performance-Led Innovation Fuels Market Distinction and Portfolio Diversity
Since June 30, 2025, OrbusNeich had actually gotten more than 250 given patents and released patent applications in crucial jurisdictions worldwide, in addition to over 55 authorized items.
Throughout the Period, the Group made development in regards to item registrations and medical trials, consisting of:
– Sapphire 3’s United States trial advancing efficiently, with client registration set to end up in Q4 2025 to support FDA submission for the CTO sign, identifying it from other standard semi-compliant balloons on the marketplace;
– Obtained CE Marks for JADE PLUS and Teleport Glide, PMDA approvals for Teleport Glide and Scoreflex QUAD, FDA approvals for the COREPASS Modular Microcatheter, and NMPA approval for the assisting catheter;
– Submitted registration applications for Scoreflex TRIO, Sapphire ULTRA, Sapphire NC ULTRA, Sapphire NC 24, JADE PLUS, Teleport XT and Teleport Glide to the NMPA, and applications for the Vascuaid Aspiration Catheter and GCE Large Lumen to the PMDA.
Concerning the Group’s robust item pipeline, the Sapphire PTX paclitaxel drug-coated balloon, in the coronary area, is set to start medical trials in Japan near completion of 2025. In the peripheral area, the JADE Score balloon is anticipated to be sent for PMDA approval in 2026.
The joint endeavor OrbusNeich P&F likewise made considerable development in the scientific trials of TricValve in the PRC, with the variety of getting involved websites increased to speed up client registration. In addition, it has actually been actively promoting TricValve’s entry into medical facilities in the Greater Bay Area (“GBA”) through the Hong Kong & & Macau Registered Drugs and Medical Devices Access to GBA Program. The very first industrial implantation of TricValve in the Mainland of China was finished in July 2025, marking the accomplishment of an essential turning point.
Multi-Region Production Bases Mitigate Evolving Geopolitical Risks
Since June 30, 2025, OrbusNeich’s aggregate yearly production capability was roughly 2.1 million balloons and stents, with production centers in Shenzhen, the PRC; Hoevelaken, the Netherlands; and Weil am Rhein, Germany. Given that obtaining eucatech AG in late 2023, the Group has actually designated resources to restore its production abilities, slowly increase output throughout the Period to provide items for both sales and scientific windows registries.
The Group finished the primary structure building of its biggest R&D and production center in Hangzhou, the PRC, in August 2025, with remodelling work anticipated to start in the 2nd half of the year. The center is set up to start operations in 2027, including a yearly production capability of 2.4 million systems.
Mr. Chien concluded, “We stay positive about the 2nd half of 2025 due to strong momentum in emerging markets, effective exclusive item launches, and tactical collaborations. APAC and EMEA will stay our essential development chauffeurs, with strategies to shift picked markets from supplier to direct sales designs to improve profits and market existence. In Europe, we will develop direct sales groups in Belgium and the Netherlands to broaden our footprint. The Japanese market will see restored momentum through brand-new item launches, while in the PRC market, we will take advantage of policy assistance to broaden item protection and speed up commercialization. United States deliveries are anticipated to accelerate in the middle of relieving tariff conflicts. Backed by OrbusNeich’s varied portfolio, strong monetary position, and economies of scale, we are well placed to construct a durable, competitive company that provides sustainable worth to stakeholders.”
About OrbusNeich Medical Group Holdings Limited
OrbusNeich is an international medical gadget business concentrating on interventional gadgets for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) treatments. Headquartered in Hong Kong, China, our Group offers its items in more than 70 nations and areas worldwide. It is likewise actively broadening into structural heart problem. With an internal R&D group boasting over 20 years of item advancement knowledge, our Group has actually established world-leading exclusive innovations.
For more details, please check out the Group’s main site: https://orbusneich.com/.
Subject: Press release summary
